Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors

计划入组 32 人 · 首次发布于 2019 年 6 月 27 日

Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors

计划入组 133 人 · 首次发布于 2021 年 12 月 6 日

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors

计划入组 200 人 · 首次发布于 2025 年 9 月 18 日

TJ101

TJ102

Phrontline Biopharma's TJ106 Shows Promise Against HER2-Low and ADC-Resistant Tumors in Preclinical Studies

Phrontline Biopharma Initiates Phase 1 Trial for TJ101 Dual-Target ADC in Solid Tumors